Business
Pipeline
| Pipeline | Potential Indication |
In-house
/Partnership |
2018 | 2019 | 2020 |
| ADC | Breast Cancer | In-house | Optimization (Linker stability, in-vitro efficacy, Synthesis) | In Vivo Efficacy / PK | GLP Tox |
| Undisclosed | Partnership | PoC | Optimization |
In Vivo Efficacy
/Toxicity |
|
| Long-acting bio pharmaceuticals | Undisclosed | In-house | PoC | Optimization |
In Vivo Efficacy
/Toxicity |
| Micelle-CoQ10 | Osteoarthritis | Partnership | Pre-clinical for IND |
IND /
Human study |
|
| Health food / Joint protection | In-house | Pre-clinical for filing | Human study | *Individual certification | |
| Sjogren’s syndrome | In-house | PoC | (depending on PoC) | ||
| Micelle-Lutein | Health food / eye | In-house | PoC | (depending on PoC) | |
